Functional Characterization of ABCA3 Genomic Variants

ABCA3 基因组变异的功能表征

基本信息

  • 批准号:
    10561718
  • 负责人:
  • 金额:
    $ 51.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-02-15 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Neonatal respiratory distress syndrome (RDS) is traditionally attributed to developmentally regulated disruption of pulmonary surfactant production. However, studies of term infants with lethal RDS have led to the discovery of genetically regulated disruption of functional surfactant production. Rare or private, biallelic, pathogenic variants in the ATP binding cassette transporter A3 gene (ABCA3) are the most common monogenic causes of neonatal RDS in term infants and childhood interstitial lung disease (chILD). ABCA3 transports phospholipids across the lamellar body limiting membrane in alveolar type II cells and is required for packaging of functional surfactant. Pathogenic ABCA3 variants encode (1) disruption of intracellular trafficking, (2) impairment of ATP- ase mediated, phospholipid transport into the lamellar body, and may also (3) activate intracellular stress and degradation pathways that disrupt lung function. Current treatments (surfactant replacement, steroids, azithromycin, and hydroxychloroquine) are non-specific and ineffective. Lung transplantation, with a 5 year survival of ~50%, remains the only treatment for progressive respiratory failure in affected infants and children. Development of variant-specific therapies for patients with pathogenic variants in the cystic fibrosis transmembrane conductance regulator gene (CFTR), a member of the ABC transporter superfamily (ABCC7), can provide a model for development of variant-specific therapies for ABCA3, although correctors will likely be gene- and variant-specific. The premise of this proposal is to develop a scalable, functional genomics platform for mechanistic characterization of ABCA3 variants and for compound screening and identification of small molecule correctors in a human, pulmonary epithelial, physiologically-relevant cell line. Specifically, we will use clonally derived A549 cell lines that stably express individual ABCA3 pathogenic variants for (1) fluorescence-based, functional assays, (2) characterization of variant-specific, pathogenic cellular degradation pathway activation, and (3) screening of FDA-approved compounds for rescue of variant-encoded ABCA3 intracellular mistrafficking and pathogenic degradation pathway activation to test hypothesis that variant-encoded ABCA3 mistrafficking and pathogenic activation of cellular stress and degradation pathways can be mechanistically characterized and can be corrected with FDA-approved small molecules. These studies will provide proof of principle for a scalable, functional, physiologically-relevant genomics platform to discover variant-specific therapies for infants and children with ABCA3 deficiency. Additionally, this genetically versatile system can be adapted and extended to discover targeted therapies for patients with other monogenic diseases that disrupt surfactant function or pulmonary epithelial cell metabolism.
项目摘要 新生儿呼吸窘迫综合征(RDS)传统上归因于发育监管的破坏 肺表面活性剂的产生。但是,对致命rd的术语婴儿的研究导致了发现 功能表面活性剂产生的遗传调节破坏。稀有或私人,双质,致病性 ATP结合盒中的变体A3基因(ABCA3)是最常见的单基因原因 新生儿RDS在儿童和儿童期间隙肺病(儿童)中。 ABCA3运输磷脂 穿过牙槽II型细胞中的层状体限制膜,是包装功能所必需的 表面活性剂。致病性ABCA3变体编码(1)破坏细胞内运输,(2)ATP- ASE介导的磷脂转运到层状体中,也可能(3)激活细胞内应力和 破坏肺功能的降解途径。当前治疗(表面活性剂替代,类固醇, 阿奇霉素和羟氯喹)是非特异性和无效的。肺移植,5年 约50%的生存仍然是受影响婴儿和儿童进行性呼吸衰竭的唯一治疗方法。 囊性纤维化中致病变异患者的变异特异性疗法的开发 跨膜电导调节基因(CFTR),ABC转运蛋白超家族的成员(ABCC7), 可以为开发ABCA3的变异特异性疗法提供模型,尽管校正可能可能是 基因和变体特异性。 该提案的前提是为机理开发可扩展的功能基因组平台 ABCA3变体的表征以及用于小分子校正器的化合物筛选和鉴定 在人类的肺上皮,生理上与与生理相关的细胞系。具体而言,我们将使用克隆派生的A549 稳定表达单个ABCA3病原变异的细胞系,用于(1)基于荧光的功能测定, (2)特异性,致病性细胞降解途径激活的表征,(3)筛选 FDA批准的化合物,用于挽救变体编码的ABCA3细胞内失调和致病性 降解途径激活以检验假设,该假设是变体编码的ABCA3失误和 细胞应激和降解途径的致病激活可以是机械表征的 并可以用FDA批准的小分子校正。 这些研究将为可扩展,功能性,生理中相关的基因组学提供原理证明 为婴儿和ABCA3缺乏症儿童发现特定于变异的疗法的平台。另外,这个 可以对遗传用途的系统进行调整并扩展,以发现针对其他患者的靶向疗法 单基因疾病破坏了表面活性剂功能或肺上皮细胞代谢。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jennifer Wambach其他文献

Jennifer Wambach的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jennifer Wambach', 18)}}的其他基金

SURFACTANT PATHWAY GENE VARIANTS AMONG INFANTS WITH RESPIRATORY DISTRESS SYNDROME
呼吸窘迫综合征婴儿的表面活性剂途径基因变异
  • 批准号:
    8293039
  • 财政年份:
    2011
  • 资助金额:
    $ 51.75万
  • 项目类别:
SURFACTANT PATHWAY GENE VARIANTS AMONG INFANTS WITH RESPIRATORY DISTRESS SYNDROME
呼吸窘迫综合征婴儿的表面活性剂途径基因变异
  • 批准号:
    8190268
  • 财政年份:
    2011
  • 资助金额:
    $ 51.75万
  • 项目类别:
SURFACTANT PATHWAY GENE VARIANTS AMONG INFANTS WITH RESPIRATORY DISTRESS SYNDROME
呼吸窘迫综合征婴儿的表面活性剂途径基因变异
  • 批准号:
    8500434
  • 财政年份:
    2011
  • 资助金额:
    $ 51.75万
  • 项目类别:
Variation in SP-C and Key UPR Genes among Infants with Respiratory Distress
呼吸窘迫婴儿 SP-C 和关键 UPR 基因的变异
  • 批准号:
    7394675
  • 财政年份:
    2008
  • 资助金额:
    $ 51.75万
  • 项目类别:

相似国自然基金

ATF6基因启动子区组蛋白甲基化对当归多糖改善ERS致心肌缺血损伤的作用机制
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    35 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Role of endothelial cell senescence in age-related cardiomyopathy
内皮细胞衰老在年龄相关性心肌病中的作用
  • 批准号:
    10726050
  • 财政年份:
    2023
  • 资助金额:
    $ 51.75万
  • 项目类别:
Immunometabolic Programs Controlled by ER Stress in Cancer
癌症中内质网应激控制的免疫代谢程序
  • 批准号:
    10713279
  • 财政年份:
    2023
  • 资助金额:
    $ 51.75万
  • 项目类别:
Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
  • 批准号:
    10637251
  • 财政年份:
    2023
  • 资助金额:
    $ 51.75万
  • 项目类别:
The impact of alcohol-induced ATF6-mediated ER stress and Golgi disorganization on pro-metastatic glycosylation of integrins in prostate cancer
酒精诱导的 ATF6 介导的 ER 应激和高尔基体解体对前列腺癌整合素促转移糖基化的影响
  • 批准号:
    10826211
  • 财政年份:
    2023
  • 资助金额:
    $ 51.75万
  • 项目类别:
Understanding GABAA receptor protein folding and misfolding
了解 GABAA 受体蛋白折叠和错误折叠
  • 批准号:
    10744869
  • 财政年份:
    2023
  • 资助金额:
    $ 51.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了